Trazodone Should NOT Be Used to Treat Sedative, Hypnotic, or Anxiolytic Dependence
The most recent and highest-quality guideline explicitly advises AGAINST using trazodone for chronic insomnia disorder due to low-quality efficacy evidence that is outweighed by its adverse effect profile 1. This recommendation directly contradicts any use of trazodone in managing sedative, hypnotic, or anxiolytic dependence, where the primary goal is to safely withdraw patients from dependency-forming medications—not substitute another potentially problematic agent.
Why Trazodone Is Inappropriate for This Indication
Guideline Evidence Against Trazodone
The 2020 VA/DoD guidelines found that trazodone (50-150 mg) showed no difference from placebo in sleep efficiency or discontinuation rates in patients with chronic insomnia 1. While it marginally improved subjective sleep quality, it failed to improve sleep onset latency, total sleep time, or wake after sleep onset. Critically, these studies had very short durations (mean 1.7 weeks) with follow-up of only 1-4 weeks—far too brief to assess safety in a population recovering from substance dependence 1.
The 2008 American Academy of Sleep Medicine guidelines note that trazodone's efficacy for insomnia "is not well established" and it is not FDA-approved for this indication 2. When sedating antidepressants like trazodone are mentioned, they are relegated to third-line options, only after benzodiazepine receptor agonists have failed, and specifically "when used in conjunction with treating comorbid depression/anxiety" 2.
The Fundamental Problem: Substituting One Sedative for Another
Patients with sedative, hypnotic, or anxiolytic dependence require withdrawal from dependency-forming substances, not replacement with another sedating medication. While trazodone has lower abuse potential than benzodiazepines 3, it still:
- Causes significant sedation and cognitive/motor impairment 4
- Has documented withdrawal symptoms upon discontinuation, including nausea, dizziness, anxiety, insomnia, and sensory disturbances 4
- Carries serious risks including orthostatic hypotension, QT prolongation, priapism, and increased bleeding risk 4
- Can cause dangerous interactions when combined with other CNS depressants 4
What the Evidence Actually Shows
The single small study (n=10) suggesting trazodone might help benzodiazepine-dependent patients 5 is methodologically weak—uncontrolled, tiny sample size, and conducted in 1993. This cannot override current high-quality guidelines advising against trazodone use.
Studies showing trazodone's utility in alcohol post-withdrawal syndrome 6 address a different clinical scenario (alcohol dependence) and do not establish efficacy for sedative-hypnotic dependence.
The Correct Approach to Sedative-Hypnotic Dependence
The evidence-based treatment for benzodiazepine and sedative-hypnotic dependence is:
- Gradual dose tapering of the original medication or cross-taper to a long-acting benzodiazepine equivalent 7
- Cognitive-behavioral therapy (CBT-I for insomnia component) 2
- Addressing underlying psychiatric comorbidities with appropriate non-sedating treatments
- Relapse prevention with ongoing psychosocial support 7
Critical Pitfalls to Avoid
- Do not substitute trazodone for benzodiazepines during withdrawal—this merely trades one problematic medication for another without addressing the underlying dependence
- Do not use trazodone as a "bridge" medication—there is no evidence supporting this strategy, and it introduces new risks
- Avoid the temptation to prescribe "something for sleep" during withdrawal—rebound insomnia is expected and temporary; behavioral interventions are more appropriate 2
When Trazodone Might Have a Role (Not for Dependence Treatment)
Trazodone may be considered only after successful withdrawal is complete and only if there is comorbid depression requiring treatment where its antidepressant properties at higher doses (150-300 mg) are the primary indication 2. Even then, it remains a second- or third-line option with limited evidence.
In summary: Trazodone has no established role in treating sedative, hypnotic, or anxiolytic dependence. The standard of care is gradual medication taper combined with behavioral interventions, not medication substitution.